Literature DB >> 30251414

The Use of Human Pluripotent Stem Cells for Modeling Liver Development and Disease.

James A Heslop1, Stephen A Duncan1.   

Abstract

The use of pluripotent stem cells (PSCs) has transformed the investigation of liver development and disease. Clinical observations and animal models have provided the foundations of our understanding in these fields. While animal models remain essential research tools, long experimental lead times and low throughput limit the scope of investigations. The ability of PSCs to produce large numbers of human hepatocyte-like cells, with a given or modified genetic background, allows investigators to use previously incompatible experimental techniques, such as high-throughput screens, to enhance our understanding of liver development and disease. In this review, we explore how PSCs have expedited our understanding of developmental mechanisms and have been used to identify new therapeutic options for numerous hepatic diseases. We discuss the future directions of the field, including how to further unlock the potential of the PSC model to make it amenable for use with a broader range of assays and a greater repertoire of diseases. Furthermore, we evaluate the current weaknesses of the PSC model and the directions open to researchers to address these limitations.
Conclusion: The use of PSCs to model human liver disease and development has and will continue to have substantial impact, which is likely to further expand as protocols used to generate hepatic cells are improved.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 30251414     DOI: 10.1002/hep.30288

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Organoid Medicine in Hepatology.

Authors:  Kokoro Sakabe; Takanori Takebe; Akihiro Asai
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-02-25

2.  iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling.

Authors:  Dongsheng Guo; Katelyn Daman; Jennifer Jc Chen; Meng-Jiao Shi; Jing Yan; Zdenka Matijasevic; Amanda M Rickard; Monica H Bennett; Alex Kiselyov; Haowen Zhou; Anne G Bang; Kathryn R Wagner; René Maehr; Oliver D King; Lawrence J Hayward; Charles P Emerson
Journal:  Elife       Date:  2022-01-25       Impact factor: 8.140

3.  Chromatin remodeling is restricted by transient GATA6 binding during iPSC differentiation to definitive endoderm.

Authors:  James A Heslop; Behshad Pournasr; Stephen A Duncan
Journal:  iScience       Date:  2022-04-25

4.  Primary human hepatocyte gene editing: Prometheus' chains are loosening.

Authors:  Eleftherios Michailidis; Ype P de Jong
Journal:  Mol Ther       Date:  2021-04-22       Impact factor: 11.454

5.  GATA6 defines endoderm fate by controlling chromatin accessibility during differentiation of human-induced pluripotent stem cells.

Authors:  James A Heslop; Behshad Pournasr; Jui-Tung Liu; Stephen A Duncan
Journal:  Cell Rep       Date:  2021-05-18       Impact factor: 9.423

6.  Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.

Authors:  Eleftherios Michailidis; Koen Vercauteren; Liliana Mancio-Silva; Linda Andrus; Cyprien Jahan; Inna Ricardo-Lax; Chenhui Zou; Mohammad Kabbani; Paul Park; Corrine Quirk; Christina Pyrgaki; Brandon Razooky; Lieven Verhoye; Irene Zoluthkin; Wei-Yu Lu; Stuart J Forbes; Luis Chiriboga; Neil D Theise; Roland W Herzog; Hiroshi Suemizu; William M Schneider; Amir Shlomai; Philip Meuleman; Sangeeta N Bhatia; Charles M Rice; Ype P de Jong
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-08       Impact factor: 11.205

7.  Characterization of Human Induced Pluripotent Stem Cell-Derived Hepatocytes with Mature Features and Potential for Modeling Metabolic Diseases.

Authors:  Gustav Holmgren; Benjamin Ulfenborg; Annika Asplund; Karin Toet; Christian X Andersson; Ann Hammarstedt; Roeland Hanemaaijer; Barbara Küppers-Munther; Jane Synnergren
Journal:  Int J Mol Sci       Date:  2020-01-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.